The Greatest Guide To P-gb-IN-1
MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage multiple intravenous doses of sifalimumab, in Grownup patients with dermatomyositis or polymyositis (NCT00533091). Major trial goals ended up To guage the protection and tolerability of sifalimumab in dermatomyositis or polymyositis